All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-06-18T10:36:45.000Z

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

By Becky Gribbell, Joshua Reid, Camilla Rossi
Featured
John C. Byrd
Jun 18, 2021
Share:

Bookmark this article

Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib superior to ibrutinib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

Byrd outlines data from the phase III ELEVATE-RR trial, a non-inferiority study which was the first to compare safety and overall survival between the BTK inhibitors acalabrutinib and ibrutinib, in patients with previously treated CLL.


More about...
AcalabrutinibASCO 2021Chronic lymphocytic leukemiasEHA 2021ELEVATE-RRIbrutinib

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

First results of a head-to-head trial of acalabrutinib versus ibrutinib in patients with high-risk CLL

Ibrutinib is a novel irreversible Bruton’s tyrosine kinase inhibitor (BTKi) approved for patients with chronic lymphocytic leukemia (CLL)/small...

Jun 24, 2021
Add bookmark

First results of a head-to-head trial of acalabrutinib versus ibrutinib in patients with high-risk CLL

Ibrutinib is a novel irreversible Bruton’s tyrosine kinase inhibitor (BTKi) approved for patients...

Jun 24, 2021
Add bookmark

What novel targeted therapies are currently under investigation for R/R CLL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What novel targeted therapies are...

Jun 12, 2021
Add bookmark

What novel targeted therapies are currently under investigation for R/R CLL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne,...

Jun 12, 2021

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox